UCB entrusts Cimzia's psoriasis prospects to Dermira
UCB has licensed its rheumatoid arthritis drug Cimzia (certolizumab pegol) to Dermira, a private US dermatology company, with the aim of getting it approved as a treatment for psoriasis.
UCB has licensed its rheumatoid arthritis drug Cimzia (certolizumab pegol) to Dermira, a private US dermatology company, with the aim of getting it approved as a treatment for psoriasis.